{"id":119513,"date":"2026-06-16T14:36:28","date_gmt":"2026-06-16T09:06:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=119513"},"modified":"2026-06-16T14:36:30","modified_gmt":"2026-06-16T09:06:30","slug":"cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/","title":{"rendered":"Cipla, Sun Pharma, Dr Reddy&#8217;s, Glenmark: Pharma Shares Fall as Centre Bans OTC Cough Syrup Sales"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Pharma shares lower June 16. Drugs (Fifth Amendment) Rules 2026 bans OTC cough syrups (notified June 9). Schedule K amended: all syrups now need prescription. Cipla, Sun Pharma, Glenmark impacted.<\/em><\/p>\n<p><strong>Pharma shares<\/strong> including <strong><a href=\"https:\/\/univest.in\/stocks\/cipla\/cipla-ltd-share-price-today\">Cipla<\/a><\/strong>, <strong><a href=\"https:\/\/univest.in\/stocks\/sunpharma\/sun-pharmaceutical-industries-ltd-share-price-today\">Sun Pharma<\/a><\/strong>, Dr Reddy&#8217;s, and <strong><a href=\"https:\/\/univest.in\/stocks\/glenmark\/glenmark-pharmaceuticals-ltd-share-price-today\">Glenmark<\/a><\/strong> are trading lower on June 16, 2026, after the Union Ministry of Health and Family Welfare notified the Drugs (Fifth Amendment) Rules, 2026 on June 9, removing the word &#8220;Syrups&#8221; from Schedule K of the Drugs Rules, 1945. This amendment effectively ends the over-the-counter (OTC) sale of all cough syrups and other liquid medicines in India &#8211; consumers must now present a valid doctor&#8217;s prescription to purchase any syrup at a pharmacy. The rule change directly impacts branded OTC cough syrup revenues for major <strong>pharma shares<\/strong> companies, with Glenmark (Alex Cough Syrup), Cipla (Benadryl), and Sun Pharma having the most visible OTC brand exposure.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=cipla-sun-pharma-dr-reddy-glenmark-cough-syrup-rule-june-16\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Pharma_Shares_Impacted_Companies_and_Products\" title=\"Pharma Shares Impacted: Companies and Products\">Pharma Shares Impacted: Companies and Products<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#The_OTC_Cough_Syrup_Rule_What_Changed_and_Why\" title=\"The OTC Cough Syrup Rule: What Changed and Why\">The OTC Cough Syrup Rule: What Changed and Why<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Pharma_Shares_Falling_Why_the_Schedule_K_Amendment_Matters\" title=\"Pharma Shares Falling: Why the Schedule K Amendment Matters\">Pharma Shares Falling: Why the Schedule K Amendment Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Background_Child_Deaths_and_WHO_Alerts_Triggered_the_Rule\" title=\"Background: Child Deaths and WHO Alerts Triggered the Rule\">Background: Child Deaths and WHO Alerts Triggered the Rule<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Pharma_Shares_Revenue_Impact_OTC_to_Prescription_Shift\" title=\"Pharma Shares Revenue Impact: OTC to Prescription Shift\">Pharma Shares Revenue Impact: OTC to Prescription Shift<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Why_are_pharma_shares_falling_today\" title=\"Why are pharma shares falling today?\">Why are pharma shares falling today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#What_is_the_Drugs_Fifth_Amendment_Rules_2026_and_what_does_it_change\" title=\"What is the Drugs Fifth Amendment Rules 2026 and what does it change?\">What is the Drugs Fifth Amendment Rules 2026 and what does it change?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Which_pharma_companies_are_most_affected_by_the_OTC_cough_syrup_ban\" title=\"Which pharma companies are most affected by the OTC cough syrup ban?\">Which pharma companies are most affected by the OTC cough syrup ban?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Why_did_the_Centre_ban_OTC_cough_syrup_sales\" title=\"Why did the Centre ban OTC cough syrup sales?\">Why did the Centre ban OTC cough syrup sales?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#How_much_of_pharma_company_revenues_come_from_OTC_cough_syrups\" title=\"How much of pharma company revenues come from OTC cough syrups?\">How much of pharma company revenues come from OTC cough syrups?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Will_the_OTC_cough_syrup_ban_permanently_reduce_pharma_revenues\" title=\"Will the OTC cough syrup ban permanently reduce pharma revenues?\">Will the OTC cough syrup ban permanently reduce pharma revenues?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#Is_there_any_chance_the_OTC_cough_syrup_ban_will_be_reversed\" title=\"Is there any chance the OTC cough syrup ban will be reversed?\">Is there any chance the OTC cough syrup ban will be reversed?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/cipla-sun-pharma-dr-reddy-glenmark-pharma-shares-cough-syrup-ban-june-16-2026\/#What_should_pharma_investors_do_given_the_cough_syrup_rule_change\" title=\"What should pharma investors do given the cough syrup rule change?\">What should pharma investors do given the cough syrup rule change?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Pharma_Shares_Impacted_Companies_and_Products\"><\/span><strong>Pharma Shares Impacted: Companies and Products<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #000000;\">\n<th style=\"color: #ffffff; padding: 8px 12px; text-align: left; font-size: 13px;\">Company<\/th>\n<th style=\"color: #ffffff; padding: 8px 12px; text-align: left; font-size: 13px;\">Key OTC Cough Syrup Products<\/th>\n<th style=\"color: #ffffff; padding: 8px 12px; text-align: left; font-size: 13px;\">Estimated Domestic Syrup Revenue Impact<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\"><a href=\"https:\/\/univest.in\/stocks\/glenmark\/glenmark-pharmaceuticals-ltd-share-price-today\">Glenmark<\/a><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Alex Cough Syrup (flagship OTC brand); Grilinctus<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Higher impact &#8211; Alex is major OTC revenue driver<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\"><a href=\"https:\/\/univest.in\/stocks\/cipla\/cipla-ltd-share-price-today\">Cipla<\/a><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Benadryl (branded codeine-based); Cofsils Cough Syrup<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Moderate impact &#8211; Benadryl is a key branded product<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\"><a href=\"https:\/\/univest.in\/stocks\/sunpharma\/sun-pharmaceutical-industries-ltd-share-price-today\">Sun Pharma<\/a><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Various branded cough and cold formulations<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Moderate impact &#8211; diversified OTC portfolio<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\"><a href=\"https:\/\/univest.in\/user\/stocks\/drreddy\/dr-reddy's-laboratories-ltd-share-price-today\">Dr Reddy&#8217;s<\/a><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">OTC cough and cold formulations<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Lower impact &#8211; relatively smaller OTC cough segment<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\"><a href=\"https:\/\/univest.in\/user\/stocks\/pfizer\/pfizer-ltd-share-price-today\">Pfizer India<\/a><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Corex (most affected historically &#8211; major OTC brand)<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Highest single-product impact if enforced strictly<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\"><a href=\"https:\/\/univest.in\/user\/stocks\/abbotindia\/abbott-india-ltd-share-price-today\">Abbott India<\/a><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Phensedyl (another large OTC cough brand)<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">High impact on this specific product<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"The_OTC_Cough_Syrup_Rule_What_Changed_and_Why\"><\/span><strong>The OTC Cough Syrup Rule: What Changed and Why<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #000000;\">\n<th style=\"color: #ffffff; padding: 8px 12px; text-align: left; font-size: 13px;\">Regulatory Parameter<\/th>\n<th style=\"color: #ffffff; padding: 8px 12px; text-align: left; font-size: 13px;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Notification<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Drugs (Fifth Amendment) Rules, 2026<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Date Notified<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">June 9, 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Amendment<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Removal of word &#8216;Syrups&#8217; from item no. 7 under Schedule K, Drugs Rules 1945<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Effect<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">All syrups (including cough syrups) now require doctor&#8217;s prescription for purchase<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Previous Status<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Schedule K allowed syrups to be sold without prescription (OTC)<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Legal Basis<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Sections 12 and 33 of Drugs and Cosmetics Act, 1940<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Draft Notification<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">December 2025 (public comments invited for 30 days)<\/td>\n<\/tr>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Background Trigger<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Child deaths from contaminated cough syrups in MP and Rajasthan; WHO global alerts<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Effective Date<\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #E0E0E0;\">Date of publication in Official Gazette (June 9, 2026)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #E8EAFF; border-radius: 14px; padding: 28px 32px 24px 32px; margin: 24px 0; cursor: pointer; max-width: 100%; box-sizing: border-box;\">\n<p style=\"font-size: 20px; font-weight: bold; color: #0a0a23; margin: 0 0 12px 0;\">Top Stocks to Watch Right Now<\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0;\">Univest analysts have shortlisted the <strong style=\"color: #0a0a23;\">Top Stocks to Buy<\/strong> based on current market momentum and 2026 sector trends.<\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 20px 0;\">Unlock the latest <a style=\"color: #3b7fff; font-weight: bold; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/log-in?redirectUrl=%2Fuser%2Fpayment%3FplanType%3DALL_PRO%2BPLANS%26cacheClear%3D1780639629052\">Top Stock Picks<\/a> on Univest<\/p>\n<p><a style=\"display: inline-block; background: #3B7FFF; color: #fff; font-size: 15px; font-weight: 600; padding: 13px 28px; border-radius: 50px; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=cipla-sun-pharma-dr-reddy-glenmark-cough-syrup-rule-june-16\" target=\"_blank\" rel=\"noopener\">See the Stocks \u2192<\/a><\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Pharma_Shares_Falling_Why_the_Schedule_K_Amendment_Matters\"><\/span><strong>Pharma Shares Falling: Why the Schedule K Amendment Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Schedule K of India&#8217;s Drugs Rules, 1945 has historically been a significant commercial enabler for pharma companies selling branded OTC products. The Schedule lists drugs that are exempt from standard drug sale licensing restrictions, allowing items like cough syrups to be sold from general stores, kirana shops, and pharmacies without any prescription requirement. This OTC accessibility was what allowed Benadryl (Cipla), Alex Cough Syrup (Glenmark), and similar branded products to achieve mass-market penetration and consistent repeat-purchase volumes.<\/p>\n<p>The Drugs Fifth Amendment removes &#8220;Syrups&#8221; from Schedule K, hurting pharma shares, as the government has ended this commercial advantage. All cough syrups &#8211; branded or generic &#8211; now require a prescription. For <strong>pharma shares<\/strong>, this means: (1) spontaneous OTC purchases at pharmacies will stop; (2) retail distribution channel dynamics change as pharmacies must maintain prescription records; (3) branded consumer recall for products like Alex or Benadryl must now be converted to doctor recommendation to sustain volumes. The total OTC cough syrup market in India is estimated at Rs 4,500-5,000 crore annually, representing a meaningful revenue stream for companies with strong branded presence in this category.<\/p>\n<p>Kunal Singal, Associate Director at Univest, notes that the pharma shares sell-off reflects both the immediate revenue headwind and the structural change in the OTC-to-prescription conversion dynamics. Glenmark faces the most direct impact because Alex Cough Syrup is a flagship OTC brand with strong consumer awareness. Cipla&#8217;s Benadryl, a well-known pharma shares OTC product, has significant retail market share. The sell-off in <strong>pharma shares<\/strong> is likely overdone in the near term for companies like Cipla and Sun Pharma, which have large prescription drug pipelines that can offset the OTC syrup impact. Glenmark, with higher OTC exposure, may see a longer-lasting revenue headwind.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Background_Child_Deaths_and_WHO_Alerts_Triggered_the_Rule\"><\/span><strong>Background: Child Deaths and WHO Alerts Triggered the Rule<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The pharma shares pressure today is the culmination of regulatory changes that has been building for over two years. Multiple children died in Madhya Pradesh and Rajasthan after consuming contaminated cough syrups adulterated with toxic chemicals. Separately, WHO issued global health alerts on India-made cough syrups linked to the deaths of over 140 children in Africa and Central Asia since 2022. A WHO alert specifically named Coldrif cough syrup, made by Tamil Nadu-based Sresan Pharmaceuticals, linked to the deaths of more than 20 children.<\/p>\n<p>These incidents prompted the Drugs Controller General of India (DCGI) to intensify inspections of cough syrup manufacturers &#8211; with 90% of manufacturers inspected in early 2026 and several found with quality lapses. The Health Ministry&#8217;s draft notification in December 2025 &#8211; proposing Schedule K amendment &#8211; was the formal step toward this rule change, and June 9&#8217;s notification converts the proposal into enforceable law. For <strong>pharma shares<\/strong>, the rule also signals that the regulatory environment for OTC consumer health products is tightening, with potential for further Schedule K amendments beyond just cough syrups.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Track Cipla, Sun Pharma and pharma sector stocks live on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Pharma_Shares_Revenue_Impact_OTC_to_Prescription_Shift\"><\/span><strong>Pharma Shares Revenue Impact: OTC to Prescription Shift<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>For pharma shares investors tracking these OTC rule changes, the key question is how material the revenue impact will be. Historical context for pharma shares is instructive: in 2016, when the government banned over 300 fixed-dose combinations (FDCs) including some cough preparations, Pfizer&#8217;s Corex-dependent revenues were significantly impacted, but the overall sector recovered as prescription volumes compensated. The current Schedule K amendment differs from an outright product ban &#8211; cough syrups are not banned, they simply require prescriptions. This means: (1) patients who visit doctors will still receive prescriptions for legitimate cough treatment; (2) the reduction in volumes will primarily come from impulse or self-medication purchases that will no longer be possible; (3) companies can invest in doctor detailing to convert OTC volume to prescription volume over 12-24 months.<\/p>\n<p>Ankit Jaiswal, Senior Research Analyst at Univest, estimates the pharma shares OTC impact at 2-4% of domestic branded revenues for companies with significant cough syrup brands. For the broader <strong>pharma shares<\/strong> sector &#8211; which includes large prescription drug exports and hospital supplies &#8211; this headwind is manageable. The sell-off in pharma shares on June 16 should be viewed as a short-term sentiment reaction rather than a fundamental re-rating, unless companies report sustained volume declines in their consumer health segments.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get live pharma share price alerts and sector regulation news in real time.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Pharma shares<\/strong> including Glenmark, Cipla, Sun Pharma and other pharma shares are under pressure on June 16, 2026, following the Centre&#8217;s June 9 notification of Drugs (Fifth Amendment) Rules, 2026 removing all syrups from Schedule K&#8217;s OTC exemption list. The rule ends over-the-counter cough syrup sales across India, requiring doctor prescriptions for all syrup purchases. Glenmark (Alex Cough Syrup) faces the highest direct exposure; Cipla (Benadryl) has significant but manageable impact. The broader pharma shares outlook remains constructive given prescription drug growth and export pipeline strength. Kunal Singal and Ankit Jaiswal at Univest advise monitoring Q1 FY27 consumer health revenue disclosures from affected pharma shares companies to assess the actual magnitude of the revenue shift.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. Please verify all data with official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_are_pharma_shares_falling_today\"><\/span><strong>Why are pharma shares falling today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Pharma shares including Cipla, Sun Pharma, Dr Reddy&#8217;s, and Glenmark are trading lower on June 16, 2026, after the Union Ministry of Health and Family Welfare notified the Drugs (Fifth Amendment) Rules, 2026 on June 9. The amendment removes the word &#8216;Syrups&#8217; from Schedule K of the Drugs Rules, 1945, effectively ending over-the-counter sale of all cough syrups and other syrups in India. Consumers will now need a valid doctor&#8217;s prescription to purchase these products from pharmacies. This rule directly impacts branded OTC cough syrup revenues for major pharma companies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Drugs_Fifth_Amendment_Rules_2026_and_what_does_it_change\"><\/span><strong>What is the Drugs Fifth Amendment Rules 2026 and what does it change?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Drugs (Fifth Amendment) Rules, 2026 amends the Drugs Rules, 1945 by removing the word &#8216;Syrups&#8217; from item number 7 under the heading &#8216;Class of Drugs&#8217; in Schedule K. Schedule K previously listed syrups (along with lozenges, certain tablets, pain balm, antacids, and other items) as medicines that could be sold without a prescription from general stores and pharmacies. By removing syrups from this Schedule K exemption list, the government has effectively ended over-the-counter sale of all syrups &#8211; including cough syrups. From June 9, 2026, pharmacies must demand a valid prescription from a registered medical practitioner before dispensing any syrup.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_companies_are_most_affected_by_the_OTC_cough_syrup_ban\"><\/span><strong>Which pharma companies are most affected by the OTC cough syrup ban?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The impact varies by company depending on their exposure to OTC cough syrup revenues. Glenmark is most directly impacted because Alex Cough Syrup, its flagship OTC cough product, is a significant revenue contributor in the branded generics segment. Cipla&#8217;s Benadryl (a codeine-based cough suppressant) is also a major branded OTC product. Sun Pharma has a range of OTC cough and cold formulations. Among non-listed companies, Pfizer India&#8217;s Corex and Abbott India&#8217;s Phensedyl are historically the largest branded OTC cough syrups in India. The total OTC cough syrup market in India is estimated at Rs 4,500-5,000 crore annually, approximately 3-5% of revenues for pharma shares companies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_the_Centre_ban_OTC_cough_syrup_sales\"><\/span><strong>Why did the Centre ban OTC cough syrup sales?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Centre&#8217;s decision to end over-the-counter cough syrup sales was triggered by two sets of concerns. First, the immediate trigger was contaminated cough syrup deaths among children in Madhya Pradesh and Rajasthan, where adulterated cough syrups containing toxic chemicals caused fatalities. Second, the global context included multiple WHO alerts on India-made cough syrups being linked to the deaths of over 140 children across Africa and Central Asia since 2022, including deaths linked to Coldrif syrup (made by Sresan Pharmaceuticals in Tamil Nadu). The draft notification was issued in December 2025 and the final rule was notified on June 9, 2026, after public comments were received and reviewed.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_of_pharma_company_revenues_come_from_OTC_cough_syrups\"><\/span><strong>How much of pharma company revenues come from OTC cough syrups?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cough and cold syrups represent approximately 5-8% of domestic branded revenues for major Indian pharma companies. For the Indian pharmaceutical industry as a whole, the respiratory segment (which includes cough syrups) accounts for approximately 17% of domestic prescription and OTC sales. Purely OTC cough syrup volumes are estimated at Rs 4,500-5,000 crore annually across India. For Glenmark, Alex Cough Syrup is among its top OTC brands. For Cipla, Benadryl contributes meaningfully to consumer health revenues. The prescription-only rule will shift some of this OTC volume to prescription-driven sales, not eliminate it entirely &#8211; patients who genuinely need cough medicine will still get prescriptions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Will_the_OTC_cough_syrup_ban_permanently_reduce_pharma_revenues\"><\/span><strong>Will the OTC cough syrup ban permanently reduce pharma revenues?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The ban is unlikely to permanently reduce pharma shares revenues by the full OTC volume, but it will change the channel. Under the new rules, patients who previously bought cough syrups OTC will now need a prescription. Some proportion of OTC cough buyers &#8211; those with mild, self-limiting coughs &#8211; may switch to alternative remedies or simply not purchase a prescription. This is the demand that pharma companies will lose. However, for patients with genuine respiratory conditions who see doctors, prescriptions will still be issued and cough syrups will still be dispensed. The net revenue impact on pharma shares is estimated at 2-3% of affected companies&#8217; domestic revenues, but it is a recurring headwind.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_there_any_chance_the_OTC_cough_syrup_ban_will_be_reversed\"><\/span><strong>Is there any chance the OTC cough syrup ban will be reversed?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Drugs Fifth Amendment &#8211; the primary catalyst for pharma shares selling today &#8211; has been formally notified in the Official Gazette and came into force on June 9, 2026. This is a legal rule change under the Drugs and Cosmetics Act, 1940, which means it cannot be easily reversed by any state government or pharmacy association. However, pharma companies or trade associations may challenge the rule in court (as Pfizer had done in 2016 during a previous OTC syrup regulation attempt). Courts had previously stayed certain cough syrup regulations. Whether similar challenges will be filed against the June 2026 amendment &#8211; which could temporarily reverse the pharma shares selling &#8211; remains to be seen. Investors should watch for any court stay orders that could temporarily pause the enforcement of the prescription requirement.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_pharma_investors_do_given_the_cough_syrup_rule_change\"><\/span><strong>What should pharma investors do given the cough syrup rule change?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Pharma shares investors should evaluate each company&#8217;s exposure to OTC cough syrup revenues individually. Glenmark is most exposed (Alex Cough Syrup is a flagship brand). Cipla has meaningful Benadryl exposure. Sun Pharma and Dr Reddy&#8217;s have lower relative OTC syrup exposure compared to prescription segments. The rule change is a headwind for FY27 revenues for pharma shares, but the sector&#8217;s diversification across prescription drugs, exports, and hospital sales provides buffer. Pharma shares investors should look for companies that can transition some OTC syrup volumes to prescription channels and have strong prescription drug pipelines to offset the consumer health impact. Always consult a SEBI-registered investment adviser before making investment decisions in pharma shares.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why are pharma shares falling today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Pharma shares including Cipla, Sun Pharma, Dr Reddy's, and Glenmark are trading lower on June 16, 2026, after the Union Ministry of Health and Family Welfare notified the Drugs (Fifth Amendment) Rules, 2026 on June 9. The amendment removes the word 'Syrups' from Schedule K of the Drugs Rules, 1945, effectively ending over-the-counter sale of all cough syrups and other syrups in India. Consumers will now need a valid doctor's prescription to purchase these products from pharmacies. This rule directly impacts branded OTC cough syrup revenues for major pharma companies.\"}},{\"@type\":\"Question\",\"name\":\"What is the Drugs Fifth Amendment Rules 2026 and what does it change?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Drugs (Fifth Amendment) Rules, 2026 amends the Drugs Rules, 1945 by removing the word 'Syrups' from item number 7 under the heading 'Class of Drugs' in Schedule K. Schedule K previously listed syrups (along with lozenges, certain tablets, pain balm, antacids, and other items) as medicines that could be sold without a prescription from general stores and pharmacies. By removing syrups from this Schedule K exemption list, the government has effectively ended over-the-counter sale of all syrups - including cough syrups. From June 9, 2026, pharmacies must demand a valid prescription from a registered medical practitioner before dispensing any syrup.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma companies are most affected by the OTC cough syrup ban?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The impact varies by company depending on their exposure to OTC cough syrup revenues. Glenmark is most directly impacted because Alex Cough Syrup, its flagship OTC cough product, is a significant revenue contributor in the branded generics segment. Cipla's Benadryl (a codeine-based cough suppressant) is also a major branded OTC product. Sun Pharma has a range of OTC cough and cold formulations. Among non-listed companies, Pfizer India's Corex and Abbott India's Phensedyl are historically the largest branded OTC cough syrups in India. The total OTC cough syrup market in India is estimated at Rs 4,500-5,000 crore annually, representing approximately 3-5% of revenues for the major pharma companies.\"}},{\"@type\":\"Question\",\"name\":\"Why did the Centre ban OTC cough syrup sales?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Centre's decision to end over-the-counter cough syrup sales was triggered by two sets of concerns. First, the immediate trigger was contaminated cough syrup deaths among children in Madhya Pradesh and Rajasthan, where adulterated cough syrups containing toxic chemicals caused fatalities. Second, the global context included multiple WHO alerts on India-made cough syrups being linked to the deaths of over 140 children across Africa and Central Asia since 2022, including deaths linked to Coldrif syrup (made by Sresan Pharmaceuticals in Tamil Nadu). The draft notification was issued in December 2025 and the final rule was notified on June 9, 2026, after public comments were received and reviewed.\"}},{\"@type\":\"Question\",\"name\":\"How much of pharma company revenues come from OTC cough syrups?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cough and cold syrups represent approximately 5-8% of domestic branded revenues for major Indian pharma companies. For the Indian pharmaceutical industry as a whole, the respiratory segment (which includes cough syrups) accounts for approximately 17% of domestic prescription and OTC sales. Purely OTC cough syrup volumes are estimated at Rs 4,500-5,000 crore annually across India. For Glenmark, Alex Cough Syrup is among its top OTC brands. For Cipla, Benadryl contributes meaningfully to consumer health revenues. The prescription-only rule will shift some of this OTC volume to prescription-driven sales, not eliminate it entirely - patients who genuinely need cough medicine will still get prescriptions.\"}},{\"@type\":\"Question\",\"name\":\"Will the OTC cough syrup ban permanently reduce pharma revenues?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The ban is unlikely to permanently reduce pharma revenues by the full OTC volume, but it will change the channel. Under the new rules, patients who previously bought cough syrups OTC will now need a prescription. Some proportion of OTC cough buyers - those with mild, self-limiting coughs - may switch to alternative remedies or simply not purchase a prescription. This is the demand that pharma companies will lose. However, for patients with genuine respiratory conditions who see doctors, prescriptions will still be issued and cough syrups will still be dispensed. The net revenue impact is estimated at 2-3% of affected companies' domestic revenues, but it is a recurring headwind as the rule is now permanent.\"}},{\"@type\":\"Question\",\"name\":\"Is there any chance the OTC cough syrup ban will be reversed?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Drugs (Fifth Amendment) Rules, 2026 have been formally notified in the Official Gazette and came into force on June 9, 2026. This is a legal rule change under the Drugs and Cosmetics Act, 1940, which means it cannot be easily reversed by any state government or pharmacy association. However, pharma companies or trade associations may challenge the rule in court (as Pfizer had done in 2016 during a previous OTC syrup regulation attempt). Courts had previously stayed certain cough syrup regulations. Whether similar challenges will be filed against the June 2026 amendment remains to be seen. Investors should watch for any court stay orders that could temporarily pause the enforcement of the prescription requirement.\"}},{\"@type\":\"Question\",\"name\":\"What should pharma investors do given the cough syrup rule change?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Pharma investors should evaluate each company's exposure to OTC cough syrup revenues individually. Glenmark is most exposed (Alex Cough Syrup is a flagship brand). Cipla has meaningful Benadryl exposure. Sun Pharma and Dr Reddy's have lower relative OTC syrup exposure compared to prescription segments. The rule change is a headwind for FY27 revenues, but the pharma sector's diversification across prescription drugs, exports, and hospital sales provides buffer. Investors should look for companies that can transition some OTC syrup volumes to prescription channels and have strong prescription drug pipelines to offset the consumer health impact. Always consult a SEBI-registered investment adviser before making any investment decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pharma shares including Cipla, Sun Pharma, Dr Reddy&#8217;s and Glenmark fell on June 16 after the Centre notified Drugs (Fifth Amendment) Rules 2026, removing &#8216;Syrups&#8217; from Schedule K of Drugs Rules 1945,<\/p>\n","protected":false},"author":34,"featured_media":119524,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[4692],"class_list":["post-119513","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-pharma-shares-fall"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1781600798:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["75"],"rank_math_title":["Cipla, Sun Pharma, Dr Reddy's, Glenmark: Pharma Shares Fall as Centre Bans OTC Cough Syrup Sales"],"rank_math_description":["Pharma shares including Cipla, Sun Pharma, Dr Reddy's and Glenmark fell on June 16 after the Centre notified Drugs (Fifth Amendment) Rules 2026, removing 'Syrups' from Schedule K of Drugs Rules 1945, ending OTC sale of all cough syrups."],"rank_math_focus_keyword":["pharma shares"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["119524"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["18348"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Cipla-Sun-Pharma-Dr-Reddy.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/119513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=119513"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/119513\/revisions"}],"predecessor-version":[{"id":119526,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/119513\/revisions\/119526"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/119524"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=119513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=119513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=119513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}